Neratinib in Combination With Ruxolitinib in Patients With mTNBC
Pilot Clinical Trial Examining the Safety and Efficacy of Neratinib in Combination With Ruxolitinib in Patients With Chemotherapy-pretreated Metastatic Triple Negative Breast Cancer With Chest Wall Recurrence
Sponsor: Baylor Research Institute
A EARLY_PHASE1 clinical study on Breast Cancer and Metastatic Triple-Negative Breast Carcinoma, this trial is actively recruiting participants. The trial is conducted by Baylor Research Institute and has accumulated 7 data snapshots since 2024. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
7 versions recorded-
Dec 2025 — Present [monthly]
Recruiting EARLY_PHASE1
-
Nov 2024 — Dec 2025 [monthly]
Recruiting EARLY_PHASE1
Status: Not Yet Recruiting → Recruiting
-
Sep 2024 — Nov 2024 [monthly]
Not Yet Recruiting EARLY_PHASE1
-
Aug 2024 — Sep 2024 [monthly]
Not Yet Recruiting EARLY_PHASE1
-
Jul 2024 — Aug 2024 [monthly]
Not Yet Recruiting EARLY_PHASE1
▶ Show 2 earlier versions
-
Dec 2023 — Jul 2024 [monthly]
Not Yet Recruiting EARLY_PHASE1
-
Sep 2023 — Dec 2023 [monthly]
Not Yet Recruiting EARLY_PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Baylor Research Institute
For direct contact, visit the study record on ClinicalTrials.gov .